Open AccessInhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin‐6 in the androgen‐independent human prostate cancer PC3 model
Author(s) -
Sakai Iori,
Miyake Hideaki,
Terakawa Tomoaki,
Fujisawa Masato
Publication year - 2011
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2011.01854.x
Subject(s) - docetaxel , autocrine signalling , small hairpin rna , protein kinase b , cell growth , in vivo , cancer research , growth inhibition , signal transduction , cell culture , biology , medicine , chemistry , endocrinology , cancer , microbiology and biotechnology , receptor , biochemistry , gene knockdown , genetics
The objective of the present study was to investigate the inhibitory effects of interleukin‐6 (IL‐6) secretion by androgen‐independent human prostate cancer PC3 cells on their growth and chemosensitivity. In this study, we established PC3 in which the expression vector containing short hairpin RNA (shRNA) targeting IL‐6 was introduced (PC3/sh‐IL6). Changes in the growth and sensitivity to docetaxel in PC3/sh‐IL6 were compared with those in PC3 transfected with control vector alone (PC3/Co). Concentration of IL‐6 in the culture supernatant from PC3/sh‐IL6 was approximately 20% of that from PC3/Co. Both in vitro and in vivo , the growth of PC3/sh‐IL‐6 was significantly inferior to that of PC3/Co, accompanying downregulation of Bcl‐2, Bcl‐xL, phosphorylated Akt, p44/42 mitogen‐activated protein kinase, and signal transducers and activation of transcription 3 in PC3/sh‐IL‐6 compared with that in PC3/Co. Despite the higher sensitivity of PC3/sh‐IL6 to docetaxel than that of PC3/Co, the secretion of IL‐6 by both cell lines was increased after treatment with docetaxel due to the formation of positive autocrine loops between these cell lines and NFκB signaling pathways. Furthermore, combined treatment with the proteasome inhibitor bortezomib, which completely inhibited the docetaxel‐induced IL‐6 secretion via the inactivation of NFκB signaling, resulted in the marked sensitization of these cell lines to docetaxel both in vitro and in vivo . These findings suggest that suppressed IL‐6 secretion using shRNA, either alone or in combination with docetaxel and bortezomib, could be a useful therapeutic strategy against androgen‐independent prostate cancer. ( Cancer Sci 2011; 102: 769–775)